| IL-17 signaling pathway |
2.05 |
7.36e-3 |
84/94 (89.36%) |
IL1B;MMP9;CXCL6;...
|
| Viral protein interaction with cytokine and cytokine re... |
1.87 |
1.47e-2 |
84/100 (84%) |
CXCL14;CXCL6;CXCL2;...
|
| Hepatocellular carcinoma |
-1.64 |
4.60e-2 |
135/168 (80.36%) |
ELK1;TXNRD1;EGFR;...
|
| Colorectal cancer |
-1.68 |
3.22e-2 |
84/86 (97.67%) |
EGFR;BAK1;PIK3R3;...
|
| Regulation of lipolysis in adipocytes |
-1.69 |
2.93e-2 |
52/55 (94.55%) |
ADCY1;ADRB3;PTGS1;...
|
| Focal adhesion |
-1.69 |
3.01e-2 |
180/201 (89.55%) |
ILK;ACTB;PPP1R12A;...
|
| Biosynthesis of unsaturated fatty acids |
-1.70 |
3.10e-2 |
21/27 (77.78%) |
BAAT;FADS2;ELOVL2;...
|
| Th1 and Th2 cell differentiation |
-1.71 |
2.49e-2 |
80/92 (86.96%) |
STAT5A;MAPK14;NFATC3;...
|
| Human T-cell leukemia virus 1 infection |
-1.74 |
1.89e-2 |
197/219 (89.95%) |
CDC16;XPO1;HLA-DOA;...
|
| TGF-beta signaling pathway |
-1.75 |
1.86e-2 |
81/94 (86.17%) |
BAMBI;BMPR2;PPP2CA;...
|
| Epstein-Barr virus infection |
-1.79 |
1.44e-2 |
189/202 (93.56%) |
NEDD4;CCND2;BAK1;...
|
| Adherens junction |
-1.80 |
1.46e-2 |
63/71 (88.73%) |
ACTB;PTPRJ;PARD3;...
|
| ECM-receptor interaction |
-1.80 |
1.56e-2 |
80/88 (90.91%) |
CD36;LAMC1;LAMC2;...
|
| Asthma |
-1.81 |
1.49e-2 |
25/31 (80.65%) |
HLA-DOA;CD40LG;HLA-DQA1;...
|
| Toxoplasmosis |
-1.82 |
1.32e-2 |
103/112 (91.96%) |
NFKBIB;PPIF;HLA-DOA;...
|
| Ferroptosis |
-1.83 |
1.21e-2 |
36/41 (87.8%) |
MAP1LC3B;SLC39A8;NCOA4;...
|
| Type I diabetes mellitus |
-1.83 |
1.34e-2 |
38/43 (88.37%) |
HLA-DQA1;HLA-DMB;IFNG;...
|
| Ovarian steroidogenesis |
-1.85 |
1.21e-2 |
41/51 (80.39%) |
ADCY2;IGF1R;SCARB1;...
|
| Phagosome |
-1.85 |
1.37e-2 |
118/152 (77.63%) |
ACTB;HLA-DOA;CD14;...
|
| Hematopoietic cell lineage |
-1.90 |
8.67e-3 |
90/99 (90.91%) |
ITGAM;KIT;HLA-DOA;...
|
| Leishmaniasis |
-1.92 |
1.01e-2 |
67/77 (87.01%) |
ITGAM;NFKBIB;HLA-DOA;...
|
| Graft-versus-host disease |
-1.93 |
2.43e-3 |
32/42 (76.19%) |
HLA-DOA;CD80;KLRD1;...
|
| Viral myocarditis |
-2.00 |
0.00e+0 |
53/60 (88.33%) |
ACTB;HLA-DOA;CD80;...
|
| Autoimmune thyroid disease |
-2.32 |
0.00e+0 |
46/53 (86.79%) |
IFNA17;IL4;CD86;...
|
| Allograft rejection |
-2.37 |
0.00e+0 |
32/38 (84.21%) |
IL4;CD86;IL2;...
|
| Antigen processing and presentation |
-2.38 |
0.00e+0 |
60/78 (76.92%) |
NFYB;HLA-DQA1;HLA-DMB;...
|
